FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:175-176 July 12, 2007 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Rennert, G. Related Article by Robson, M. PubMed Citation

Learning whether a patient who has just been given a diagnosis of breast cancer also bears one of the cancer-causing mutations in the BRCA1 or BRCA2 genes may add little to the clinician's ability to select a therapy or predict the course of disease, once the grade and receptor status of the tumor and the age of the patient are taken into account. In this issue of the Journal, Rennert et al.¹ support that line of reasoning with their study of Israeli women in whom breast cancer was diagnosed in 1987 or 1988. Reliable data on clinical outcomes in carriers . . . [Full Text of this Article]

Source Information

From the Epidemiology and Biostatistics Program, National Cancer Institute, Bethesda, MD.

This article has been cited by other articles:

• Lynch, H. T., Marcus, J. N., Rubinstein, W. S. (2008). Stemming the Tide of Cancer for BRCA1/2 Mutation Carriers. JCO 26: 4239-4243 [Full Text]  
• (2007). Does Breast Cancer Survival Have a Genetic Basis?. JWatch Women's Health 2007: 3-3 [Full Text]